Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options.

Rivera E.

Breast J. 2010 May-Jun;16(3):252-63. doi: 10.1111/j.1524-4741.2009.00896.x. Epub 2010 Apr 12. Review.

PMID:
20408828
2.

Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.

Ho J, Zhang L, Todorova L, Whillans F, Corey-Lisle P, Yuan Y.

J Manag Care Pharm. 2009 Jul-Aug;15(6):467-75.

3.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.

Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH.

Breast Cancer Res Treat. 2010 Jul;122(2):409-18. doi: 10.1007/s10549-010-0901-4. Epub 2010 May 8.

PMID:
20454927
4.

Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.

Rivera E.

Am J Clin Oncol. 2010 Apr;33(2):176-85. doi: 10.1097/COC.0b013e3181931049. Review.

PMID:
19675449
5.

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.

Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, Peck R, Thomas E.

Clin Breast Cancer. 2008 Jun;8(3):234-41. doi: 10.3816/CBC.2008.n.026.

PMID:
18650153
6.

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH.

J Clin Oncol. 2007 Nov 20;25(33):5210-7. Epub 2007 Oct 29.

PMID:
17968020
7.

Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.

Wang J, Fan Y, Xu B.

Cancer Chemother Pharmacol. 2010 Aug;66(3):597-603. doi: 10.1007/s00280-010-1362-5. Epub 2010 May 21.

PMID:
20490795
8.

Preclinical discovery of ixabepilone, a highly active antineoplastic agent.

Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.

Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Review.

PMID:
18347795
9.

Ixabepilone, a new treatment option for metastatic breast cancer.

Toppmeyer DL, Goodin S.

Am J Clin Oncol. 2010 Oct;33(5):516-21. doi: 10.1097/COC.0b013e3181b9cd52. Review.

PMID:
20023567
10.

Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.

Yardley DA.

Clin Breast Cancer. 2008 Dec;8(6):487-92. doi: 10.3816/CBC.2008.n.058. Review.

PMID:
19073502
11.
12.

Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.

Fornier M.

Clin Breast Cancer. 2010 Oct 1;10(5):352-8. doi: 10.3816/CBC.2010.n.046. Review.

PMID:
20920979
13.

The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.

Boehnke Michaud L.

J Oncol Pharm Pract. 2009 Jun;15(2):95-106. doi: 10.1177/1078155208100095. Epub 2009 Jan 26. Review.

PMID:
19171553
14.

Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.

Rak Tkaczuk KH.

Breast Cancer (Auckl). 2011 Jan 13;5:1-14. doi: 10.4137/BCBCR.S5331.

15.

Clinical experience with epothilones in patients with breast cancer.

Buzdar AU.

Clin Breast Cancer. 2008 Mar;8 Suppl 2:S71-8. Review.

PMID:
18637402
16.

Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.

Aogi K, Rai Y, Ito Y, Masuda N, Watanabe J, Horiguchi J, Tokudome T, Takashima S.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1427-33. doi: 10.1007/s00280-013-2140-y. Epub 2013 Mar 28.

PMID:
23536163
17.

Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.

Vahdat LT, Vrdoljak E, Gómez H, Li RK, Bosserman L, Sparano JA, Baselga J, Mukhopadhyay P, Valero V.

J Geriatr Oncol. 2013 Oct;4(4):346-52. doi: 10.1016/j.jgo.2013.07.006. Epub 2013 Aug 23.

PMID:
24472478
18.

Ixabepilone for the treatment of breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

Ann Med. 2011;43(6):477-86. doi: 10.3109/07853890.2011.579151. Epub 2011 May 17. Review.

PMID:
21585248
19.

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.

Perez EA.

Breast Cancer Res Treat. 2009 Mar;114(2):195-201. doi: 10.1007/s10549-008-0005-6. Epub 2008 Apr 29. Review.

PMID:
18443902
20.

Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.

Goodin S.

Am J Health Syst Pharm. 2008 Nov 1;65(21):2017-26. doi: 10.2146/ajhp070628. Review.

PMID:
18945860

Supplemental Content

Support Center